Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial

Keyphrases

• Placebo-controlled Trial 100%
• Active Ulcerative Colitis 100%
• Curcumin 100%
• Placebo 40%
• Clinical Remission 30%
• Clinical Response 30%
• Ulcerative Colitis Patient 20%
• Cytochrome P450 1A1 (CYP1A1) 20%
• Simple Clinical Colitis Activity Index 20%
• Mayo Endoscopic Subscore 20%
• Co-primary 20%
• Israel 10%
• Receptor Activation 10%
• Response Rate 10%
• Between-group 10%
• 3-point 10%
• Placebo Groups 10%
• Greece 10%
• Adverse Events 10%
• Remission 10%
• Index Score 10%
• Targeted Treatment 10%
• Calprotectin 10%
• Fecal Calprotectin 10%
• Response Reduction 10%
• Clinical Biomarkers 10%
• Open-label Trial 10%
• Aryl Hydrocarbon Receptor 10%
• Objective Response 10%
• Mesalamine 10%
• Enteric Coating 10%
• Mucosal Expression 10%
• Endoscopic Improvement 10%
• Biomarker Response 10%
• Ulcerative Colitis Therapy 10%
• Herbal Combination 10%
• Aryl Hydrocarbon Receptor Pathway 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Ulcerative Colitis 100%
• Curcumin 100%
• Remission 40%
• Colitis 20%
• Calgranulin 20%
• Aromatic Hydrocarbon Receptor 20%
• Cytochrome P450 1A1 20%
• Biological Marker 10%
• Adverse Event 10%
• Biological Product 10%
• Open-Label Trial 10%
• Aminosalicylic Acid 10%

Medicine and Dentistry

• Placebo 100%
• Ulcerative Colitis 100%
• Curcumin 100%
• Colitis 20%
• Aromatic Hydrocarbon Receptor 20%
• Cytochrome P450 1A1 20%
• Biological Marker 10%
• Adverse Event 10%
• Biological Product 10%
• Faecal Calprotectin 10%
• Calgranulin 10%
• Open-Label Trial 10%
• Mesalazine 10%